Flu season is almost here, and there is a respiratory syncytial virus (RSV) vaccine update worth monitoring. Earlier today, the Food and Drug Administration (FDA) put a clinical hold on the combination and standalone influenza shot developed by Novavax Inc (NASDAQ:NVAX). NVAX Testing Chart Support NVAX is down 17.7% to trade at $10.36 in response, on track for its lowest close since mid May. The shares are still up 115% in 2024 though, and the round-number $10 level -- an area that coincides with its 160-da ...